Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Hard to fault but overvalued

Wesfarmers
3:27pm
August 28, 2025
WES’s FY25 result was largely in line with expectations. Earnings for most divisions were in line with our forecasts. Health was a standout with a stronger-than-expected jump in earnings. The announcement of a $1.50ps capital return (comprising a fully-franked special dividend of $0.40ps and capital component of $1.10ps) was another highlight. Management said the retail divisions traded well in the first 8 weeks of FY26. Encouragingly, they have seen a modest improvement in consumer demand on the back of a moderation in inflation and the recent interest rate cuts. We make minimal changes to earnings forecasts but lift our target price to $83.20 (from $75.80). This reflects another solid result, demonstrating strong execution by management and early signs of improvement in consumer sentiment, which should support a more positive outlook for trading conditions. With a forecast 12-month TSR of -6%, we maintain our TRIM rating. While we continue to view WES as a core long-term portfolio holding with a diversified group of well-known retail and industrial brands, a healthy balance sheet, and an experienced leadership team with a strong track record of growth, trading on 36.9x FY26F PE we see the stock as overvalued in the short term.

Healthy earnings, but guidance reset weighs

South32
3:27pm
August 28, 2025
FY25 result steady, but FY26 guidance reset at Mozal (C&M risk) and Cannington (lower throughput, higher costs) clouds near-term earnings. Hermosa build year pushes group capex to US$1.4bn in FY26, keeping FCF tight despite trimmed sustaining spend. Sierra Gorda copper volumes up 20%, but limited near-term catalysts and consensus downgrades pressure weigh on sentiment. Dividend of US 2.6cps; US$144m remains in buyback program. Maintain BUY with reduced target price of A$3.55 (was A$4.10).

More Supply Agreements needed

Micro-X
3:27pm
August 28, 2025
MX1 posted its FY25 result, which was behind our forecasts. Lower product sales was the area we underestimated. However, the recent signing of a Supply Agreement with a major healthcare provider should see sales of the Rover Plus increase in FY26 and FY27. We expect similar agreements are likely to follow. The focus on medical imaging appears to be paying off. We have made no changes to our forecasts and our target price remains unchanged at A$0.17. We maintain our SPECULATIVE BUY recommendation.

Brighter future ahead

Beacon Lighting
3:27pm
August 28, 2025
BLX reported NPAT decline of 0.7% on an underlying basis, which was ~7% lower than expected driven by lower LFL sales and higher operating costs. Encouragingly, sales momentum improved through the year and accelerated in the 4Q, and has been maintained into FY26. Trade sales continues to grow, with top line sales up >20%. Trade now represents 40% of relevant sales and the company remains on track for 50/50 split trade and retail by FY28. We have lowered our NPAT forecasts by 9%/7% respectively in FY26/27, pushing out the strong earnings recovery and operating leverage into FY27. We expect significant leverage in this business when consumer sentiment and housing cycle turns. We have upgraded to an ACCUMULATE, with a $3.80 TP (was $3.55).

Stabilising operations appear priced in

Mineral Resources
3:27pm
August 28, 2025
MIN delivered a solid FY25 result with EBITDA ahead of forecasts and underlying NPAT well ahead of forecasts on lower D&A and net interest. FY26 guidance was in line, although MorgansF/consensus were at the top-end of guidance. MIN confirmed Onslow has been running at a 35mtpa run rate for the last 4 weeks, and the haul road repair will complete in mid-September. We move to a TRIM rating with a A$34ps target price (previously A$31ps) reflecting our view that MIN’s stabilising operations are already priced in following its strong share price run.

Putting the trade back in the shade

Clinuvel Pharmaceuticals
3:27pm
August 28, 2025
FY25 result itself was marginally below expectations with higher-than-expected expenses delivered a miss to profit lines and a continued failure to change the narrative around capital management and disclosures which continues to keep a lid on the upside. Seasonal 2H strength carried the year along with margins still flattered by low materials costs which we expect will normalise in FY26. Cash balance remains an eyesore, now up to A$224m (~35% of market cap), and buy-back capacity effectively untouched and no uplift in dividend. We called CUV out as a potential beat candidate in our pre-reporting season report given the seasonally strong trading period, but happy to close out following a strong SP appreciation in the leadup. Our target price reduces to A$14 (from A$15) and we downgrade to a HOLD recommendation.

Backlog support underpins favorable outlook

Worley
3:27pm
August 28, 2025
WOR delivered a solid FY25 result, which came broadly in line with MorgF and consensus, with Underlying EBITA of $823m (+10% YoY), driven by Aggregate revenue growth 4%, Underlying EBITA margin (ex-procurement) improved 130bps. WOR’s outlook for FY26 remains positive with the group flagging that they are not seeing any material project cancellations, across end markets, providing confidence in moderate revenue growth & stable EBITA margins in FY26. We trim our Underlying EBITA forecast by -2%, in FY26/27F, to align more closely with the Groups outlook. This sees us retain our BUY rating and price target of $16.80/sh).

Shaping up for sales growth in FY26

ImpediMed
3:27pm
August 28, 2025
IPD posted its FY25 result reporting a net loss higher than our forecast. Importantly, the operating cash outflow was better than our expectations. Our focus is the growth of the installed base in the US which now seems to be gaining momentum with 4Q25 delivering a record 44 SOZO units. We expect subsequent quarters to continue to build on this. We have made modest downgrades to our short-term forecasts, which sees our valuation move to A$0.14 (from A$0.15). We maintain a SPECULATIVE BUY recommendation on IPD.

Prescription pressures

Ebos Group
3:27pm
August 28, 2025
EBO’s FY26 results were marginally below expectations, however the key disappointment lies in guidance which signaled a more cautious outlook, reflecting competitive pressures in pharmacy, softer hospital demand, and ongoing consumer weakness in discretionary categories. All issues potentially impacting negative sentiment into FY26 but we remind investors of EBO’s long history of strong EPS growth and consistent return on capital along with a growing dividend stream. Our target price moderates to A$34.82 but we retain an Accumulate rating.

Rare rewards

Neuren Pharmaceuticals
3:27pm
August 28, 2025
NEU delivered a strong first half, underpinned by continued growth in royalties resulting in a solid uplift in profitability. Operationally, momentum remains strong with record DAYBUE patient uptake in the US and progress toward global expansion and late-stage clinical programs. Key near-term drivers include continued DAYBUE uptake with quarterly updates from Acadia (ongoing), EU marketing authorisation decision expected in 1Q26, initiation of the Japan clinical trial in 3Q25, progress on the Ph3 PMS trial (site activations and enrollment updates through 2025), and FDA interactions for Pitt Hopkins and HIE programs later in 2025. Consensus target prices remain materially higher than current levels, sitting at A$23.86 per share, all with BUY recommendations.

News & insights

Michael Knox discusses how weakening US labour market conditions have prompted the Fed to begin easing, with expectations for further cuts to a neutral rate that could stimulate Indo-Pacific trade.


In our previous discussion on the Fed, we suggested that the deterioration in the US labour market would move the Fed toward an easing path. We have now seen the Fed cut rates by 25 basis points at the September meeting. As a result, the effective Fed funds rate has fallen from 4.35% to 4.10%.

Our model of the Fed funds rate suggests that the effective rate should move toward 3.35%. At this level, the model indicates that monetary policy would be neutral.

The Summary of Economic Projections from Federal Reserve members and Fed Presidents also suggests that the Fed funds rate will fall to a similar level of 3.4% in 2026.

We believe this will happen by the end of the first quarter of 2026. In fact, the Summary of Economic Projections expects an effective rate of 3.6% by the end of 2025.

The challenge remains the gradually weakening US labour market, with unemployment expected to rise from 4.3% now to 4.5% by the end of 2025. This is then projected to fall very slowly to 4.4% by the end of 2026 and 4.3% by the end of 2027.

These expectations would suggest one of the least eventful economic cycles in recent history. We should be so lucky!

In the short term, it is likely that the Fed will cut the effective funds rate to 3.4% by March 2026.

This move to a neutral stance will have a significant effect on the world trade cycle and on commodities. The US dollar remains the principal currency for financing trade in the Indo-Pacific. Lower US short-term rates will likely generate a recovery in the trade of manufacturing exports in the Indo-Pacific region, which in turn will increase demand for commodities.

The Fed’s move to a neutral monetary policy will generate benefits well beyond the US.

Read more
Michael Knox discusses the RBA’s decision to hold rates in September and outlines the conditions under which a November rate cut could occur, based on trimmed mean inflation data.

Just as an introduction to what I'm going to talk about in terms of Australian interest rates today, we'll talk a little bit about the trimmed mean, which is what the RBA targets. The trimmed mean was invented by the Dallas Fed and the Cleveland Fed. What it does is knock out the 8% of crazy high numbers and the 8% of crazy low numbers.

That's the trimming at both ends. So the number you get as a result of the trimmed mean is pretty much the right way of doing it. It gets you to where the prices of most things are and where inflation is. That’s important to understand what's been happening in inflation.

With that, we've seen data published for the month of July and published in the month of August, which we'll talk about in a moment. Back in our remarks on the 14th of August, we said that the RBA would not cut in September. That was at a time when the market thought there would be a September return. But we thought they would wait until November. So with the RBA leaving the cash rate unchanged on the 30th of September, is it still possible for a cut in November?

The RBA released its statement on 30th September, and that noted that recent data, while partial and volatile, suggests that inflation in the September quarter may be higher than expected at the time of the August Statement on Monetary Policy. So what are they talking about? What are they thinking about when they say that? Well, it could be that they’re thinking about the very sharp increases in electricity prices in the July and August monthly CPIs.

In the August monthly CPI, even with electricity prices rising by a stunning 24.6% for the year to August faster than the 13.6% for the year to July; the trimmed mean still fell from 2.7% in the year to July to 2.6% in the year to August. Now, a similar decline in September would take that annual inflation down to 2.4%.

The September quarter CPI will be released on the 29th of October. Should it show a trimmed mean of 2.5% or lower, then we think that the RBA should provide a rate cut in November. This would provide cheer for homeowners as we move towards the festive season. Still, it all depends on what we learn from the quarterly CPI on the 29th of October.

Read more
In recent days, several people have asked for my updated view on the Federal Reserve and the Fed funds rate, as well as the outlook for the Australian cash rate. I thought I’d walk through our model for the Fed funds rate and explain our approach to the RBA’s cash rate.

In recent days, several people have asked for my updated view on the Federal Reserve and the Fed funds rate, as well as the outlook for the Australian cash rate. I thought I’d walk through our model for the Fed funds rate and explain our approach to the RBA’s cash rate.

It’s fascinating to look at the history of the current tightening cycle. The Fed began from a much higher base than the RBA, and in this cycle, they reached a peak rate of 535 basis points, compared to the RBA’s peak of 435 basis points. For context, in the previous tightening cycle, the RBA reached a peak of 485 basis points.

The reason the RBA was more cautious this time around is largely due to an agreement between Treasurer Jim Chalmers and the RBA. The goal was to implement rate increases that would not undo the employment gains made in the previous cycle. As a result, the RBA was far less aggressive in its approach to rate hikes.

This divergence in peak rates is important. Because the Australian cash rate peaked lower, the total room for rate cuts and the resulting stimulus to the economy is significantly smaller than in previous cycles.

The Fed, on the other hand, peaked at 535 basis points in August last year and began cutting rates shortly after. By the end of December, they had reduced the rate to 435 basis points, where it has remained since.

Recent U.S. labour market data shows a clear slowdown. Over the past 20 years, average annual employment growth in the U.S. has been around 1.6 percent, but this fell to 1.0 percent a few months ago and dropped further to 0.9 percent in the most recent data.

This suggests that while the Fed has successfully engineered a soft landing by slowing the economy, it now risks tipping into a hard landing if rates remain unchanged.

Fed Funds Rate Model Update

Our model for the Fed funds rate is based on three key variables: inflation, unemployment, and inflation expectations. While inflation has remained relatively stable, inflation expectations have declined significantly, alongside the drop in employment growth.

As a result, our updated model now estimates the Fed funds rate should be around 338 basis points, which is 92 basis points lower than the current rate of 435. This strongly suggests we are likely to see a 25 basis point cut at the Fed’s September 17 meeting.

There are two more Fed meetings scheduled for the remainder of the year, one in October and another on December 10. However, we will need to review the minutes from the September meeting before forming a view on whether further cuts are likely.

Australian Cash Rate Outlook

Turning to the Australian cash rate, as mentioned, the peak this cycle was lower than in the past, meaning the stimulatory effect of rate cuts is more limited.

We have already seen three rate cuts, and the key question now is whether there will be another at the RBA’s 4 November meeting.

This decision hinges entirely on the September quarter inflation data, which will be released on 29 October 2025.

The RBA’s strategy is guided by the concept of the real interest rate. Over the past 20 years, the average real rate has been around 0.85 percent. Assuming the RBA reaches its 2.5 percent inflation target, this implies a terminal cash rate of around 335 basis points. Once that level is reached, we expect it will mark the final rate cut of this cycle, unless inflation falls significantly further.

So, will we see a rate cut in November?

It all depends on the trimmed mean inflation figure for the September quarter. If it comes in at 2.5 percent or lower, we expect a rate cut. The June quarter trimmed mean was 2.7 percent, and the monthly July figure was 2.8 percent. If the September figure remains the same or rises, there will be no cut. Only a drop to 2.5 percent or below will trigger another move.

We will have a much clearer picture just a few days before Melbourne Cup Day.

Read more